Will Ozempic bankrupt the U.S. healthcare system? - Los Angeles Times
Providing GLP-1 drugs to 19.7 million Medicare beneficiaries with obesity would cost $268 billion a year, researchers estimate in a recent study.| Los Angeles Times
Providing GLP-1 drugs to 19.7 million Medicare beneficiaries with obesity would cost $268 billion a year, researchers estimate in a recent study.| Los Angeles Times
Those new weight-loss drugs will slash spending on obesity-related illness, so why is it so hard to get insurers to cover them?| Los Angeles Times
We’re giving subscribers early or entirely exclusive access to this journalism.| Los Angeles Times
GLP-1s or obesity drugs are growing in popularity. What does this mean for sectors ranging from biotech to insurance and food?| www.jpmorgan.com
